

The following list of recommended PDL changes were reviewed and approved by the MHS P&T Committee on April 12th, 2017.

**Table 1: Summary of PDL Terminations – Effective 8/1/2017**

Drug Name	Ingredients	Dosage Form	Strength	Notes
Nevanac	Nepafenac	Ophthalmic suspension	0.1%	Remove from PDL, prefer Diclofenac 0.1% soln, Ketorolac 0.5% solution
Lantus	Insulin glargine	Vial pens	100 unit/ml	Prefer Basaglar (insulin glargine) 100 unit/ml  Grandfather current utilizers for 90 days and send member and provider notices. Claim surveillance for missed fills.
Lidocaine		Ointment	5%	Prefer Lidocaine 4% cream

